333 related articles for article (PubMed ID: 26704388)
41. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
42. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.
Lucas KM; Mohana-Kumaran N; Lau D; Zhang XD; Hersey P; Huang DC; Weninger W; Haass NK; Allen JD
Clin Cancer Res; 2012 Feb; 18(3):783-95. PubMed ID: 22173547
[TBL] [Abstract][Full Text] [Related]
43. The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53.
Reuland SN; Goldstein NB; Partyka KA; Cooper DA; Fujita M; Norris DA; Shellman YG
PLoS One; 2011; 6(8):e24294. PubMed ID: 21897876
[TBL] [Abstract][Full Text] [Related]
44. Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner.
Kiprianova I; Remy J; Milosch N; Mohrenz IV; Seifert V; Aigner A; Kögel D
Neoplasia; 2015 Jul; 17(7):564-73. PubMed ID: 26297434
[TBL] [Abstract][Full Text] [Related]
45. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).
Konopleva M; Watt J; Contractor R; Tsao T; Harris D; Estrov Z; Bornmann W; Kantarjian H; Viallet J; Samudio I; Andreeff M
Cancer Res; 2008 May; 68(9):3413-20. PubMed ID: 18451169
[TBL] [Abstract][Full Text] [Related]
46. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.
Bogenberger JM; Kornblau SM; Pierceall WE; Lena R; Chow D; Shi CX; Mantei J; Ahmann G; Gonzales IM; Choudhary A; Valdez R; Camoriano J; Fauble V; Tiedemann RE; Qiu YH; Coombes KR; Cardone M; Braggio E; Yin H; Azorsa DO; Mesa RA; Stewart AK; Tibes R
Leukemia; 2014 Aug; 28(8):1657-65. PubMed ID: 24451410
[TBL] [Abstract][Full Text] [Related]
47. Bcl-2 modulation to activate apoptosis in prostate cancer.
Bray K; Chen HY; Karp CM; May M; Ganesan S; Karantza-Wadsworth V; DiPaola RS; White E
Mol Cancer Res; 2009 Sep; 7(9):1487-96. PubMed ID: 19737977
[TBL] [Abstract][Full Text] [Related]
48. Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia.
Wang X; Mak PY; Mu H; Tao W; Rao A; Visweswaran R; Ruvolo V; Pachter JA; Weaver DT; Andreeff M; Xu B; Carter BZ
Mol Cancer Ther; 2020 Aug; 19(8):1636-1648. PubMed ID: 32404407
[TBL] [Abstract][Full Text] [Related]
49. Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737.
Wiegmans AP; Alsop AE; Bots M; Cluse LA; Williams SP; Banks KM; Ralli R; Scott CL; Frenzel A; Villunger A; Johnstone RW
Cancer Res; 2011 May; 71(10):3603-15. PubMed ID: 21398407
[TBL] [Abstract][Full Text] [Related]
50. Synergistic AML Cell Death Induction by Marine Cytotoxin (+)-1(
Florean C; Kim KR; Schnekenburger M; Kim HJ; Moriou C; Debitus C; Dicato M; Al-Mourabit A; Han BW; Diederich M
Mar Drugs; 2018 Dec; 16(12):. PubMed ID: 30572618
[TBL] [Abstract][Full Text] [Related]
51. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.
Kojima K; Konopleva M; Samudio IJ; Schober WD; Bornmann WG; Andreeff M
Cell Cycle; 2006 Dec; 5(23):2778-86. PubMed ID: 17172851
[TBL] [Abstract][Full Text] [Related]
52. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
Thijssen R; Diepstraten ST; Moujalled D; Chew E; Flensburg C; Shi MX; Dengler MA; Litalien V; MacRaild S; Chen M; Anstee NS; Reljić B; Gabriel SS; Djajawi TM; Riffkin CD; Aubrey BJ; Chang C; Tai L; Xu Z; Morley T; Pomilio G; Bruedigam C; Kallies A; Stroud DA; Bajel A; Kluck RM; Lane SW; Schoumacher M; Banquet S; Majewski IJ; Strasser A; Roberts AW; Huang DCS; Brown FC; Kelly GL; Wei AH
Blood; 2021 May; 137(20):2721-2735. PubMed ID: 33824975
[TBL] [Abstract][Full Text] [Related]
53. Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients.
Jilg S; Reidel V; Müller-Thomas C; König J; Schauwecker J; Höckendorf U; Huberle C; Gorka O; Schmidt B; Burgkart R; Ruland J; Kolb HJ; Peschel C; Oostendorp RA; Götze KS; Jost PJ
Leukemia; 2016 Jan; 30(1):112-23. PubMed ID: 26153654
[TBL] [Abstract][Full Text] [Related]
54. The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA.
Muenchow A; Weller S; Hinterleitner C; Malenke E; Bugl S; Wirths S; Müller MR; Schulze-Osthoff K; Aulitzky WE; Kopp HG; Essmann F
Cell Death Dis; 2020 Aug; 11(8):701. PubMed ID: 32839432
[TBL] [Abstract][Full Text] [Related]
55. Combination of ABT-737 and resveratrol enhances DNA damage and apoptosis in human T-cell acute lymphoblastic leukemia MOLT-4 cells.
Opydo-Chanek M; Rak A; Cierniak A; Mazur L
Toxicol In Vitro; 2017 Aug; 42():38-46. PubMed ID: 28366708
[TBL] [Abstract][Full Text] [Related]
56. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
57. BH3 mimetic ABT-737 induces apoptosis in CD34
Rao J; Li F; Zhang RY; Zhou HH; Chen GA
Asia Pac J Clin Oncol; 2017 Apr; 13(2):e144-e152. PubMed ID: 26552712
[TBL] [Abstract][Full Text] [Related]
58. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
Russo M; Spagnuolo C; Volpe S; Tedesco I; Bilotto S; Russo GL
Biochem Pharmacol; 2013 Apr; 85(7):927-36. PubMed ID: 23353698
[TBL] [Abstract][Full Text] [Related]
59. Epothilone B induces apoptosis and enhances apoptotic effects of ABT-737 on human cancer cells via PI3K/AKT/mTOR pathway.
Li YL; Sun J; Hu X; Pan YN; Yan W; Li QY; Wang F; Lin NM; Zhang C
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2281-9. PubMed ID: 27591861
[TBL] [Abstract][Full Text] [Related]
60. Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.
Vachhani P; Bose P; Rahmani M; Grant S
Physiol Genomics; 2014 Jul; 46(13):448-56. PubMed ID: 24824212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
